Search This Blog

Thursday, May 28, 2026

SciSparc unit gets conditional TSX Venture Exchange OK for ~ $9.5 m share deal for 54% of CliniQuantum

 

SciSparc unit NeuroThera receives conditional TSX Venture Exchange approval for approximately $9.5 million share deal for 54% of CliniQuantum

  • NeuroThera Labs, a majority-owned subsidiary of SciSparc, is leading the CliniQuantum acquisition.
  • Deal terms were amended and the closing deadline extended to June 1, 2026.
  • CliniQuantum is described as a quantum clinical-trial analytics firm by SciSparc.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)